RecruitingPhase 1NCT05488522

SBRT With Atezo/Bev for HCC

A Phase I Study of SBRT Vaccination With Atezolizumab and Bevacizumab for Patients With Advanced Hepatocellular Carcinoma

Sponsor

Abramson Cancer Center at Penn Medicine

Enrollment

18 participants

Start Date

Sep 1, 2022

Study Type

INTERVENTIONAL

Conditions

Hepatocellular Carcinoma

Summary

A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a combination of a focused radiation treatment called SBRT with two immunotherapy drugs — atezolizumab and bevacizumab — in patients with liver cancer (hepatocellular carcinoma, or HCC). The goal is to see if targeting tumors with radiation while also using drugs that boost the immune system can improve outcomes. **You may be eligible if...** - You have hepatocellular carcinoma (liver cancer) - Your cancer cannot be removed by surgery or treated with ablation (burning/freezing the tumor) - Systemic (whole-body) therapy has been recommended for you **You may NOT be eligible if...** - Your cancer can be treated with surgery or ablation - No specific additional exclusion criteria were listed Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALSBRT + atezolizumab and bevacizumab

Stereotactic Body Radiotherapy (SBRT) is a radiation procedure that delivers precise doses of radiation in fractions. See following section for more information on the schedule, dose, volume, and simulation of SBRT. Atezolizumab is an FDA-approved immune checkpoint inhibitor that is used in the treatment of advanced HCC. It is administered as a flat-dose 1200 mg intravenous infusion every three weeks. Bevacizumab is an FDA-approved anti-VEGF monoclonal antibody that is used in the treatment of advanced HCC in combination with atezolizumab. It is administered as a weight-based dose of 15 mg/kg intravenous infusion every 3 weeks.